Microtransplantation: clinical applications and mechanisms

Current Opinion in Hematology
Bo CaiHui-Sheng Ai

Abstract

Microtransplantation (MST) has been successfully used to manage patients with hematological malignancies, especially older patients with acute myeloid leukemia (AML). Recent clinical applications and mechanistic studies of MST are reviewed. MST improves complete remission rates which have no significant difference among age groups in older patients with AML. Sufficient courses of postremission therapy lead to prolonged overall survival and reduced relapse rate. MST also benefits young patients with low-risk or intermediate-risk AML who lack a human leukocyte antigen-identical donor and shows therapeutic potential extending to other malignancies. Both donor and recipient-derived T cells contribute to the antileukemic effect. Novel methods to monitor donor microchimerism and donor-recipient immune cell interaction may further unveil mechanisms of MST. MST shows therapeutic efficacy to several hematological malignancies, whereas mechanistic studies still need to be promoted, and its combination with other targeted therapies is warranted to further reduce relapse rate.

References

Jun 1, 1969·The Journal of Experimental Medicine·K RajewskyN K Jerne
Feb 1, 1997·Immunological Reviews·A SelvakumarB Dupont
Jan 16, 1998·Immunity·M UhrbergP Parham
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Jul 18, 1964·Lancet·E J DELORME, P ALEXANDER
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Apr 7, 2007·Blood·Shahram Y KordastiGhulam J Mufti
Apr 16, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Heather J SymonsEphraim J Fuchs
Aug 30, 2008·Cancer Biology & Therapy·Xiangli ChenXiaorong Ma
Sep 2, 2008·Immunological Reviews·Brian T Fife, Jeffrey A Bluestone
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gerald A ColvinPeter J Quesenberry
May 7, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miroslaw J SzczepanskiMichael Boyiadzis
May 20, 2009·Leukemia & Lymphoma·Margot JakMarinus H J Van Oers
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arati V RaoBob Löwenberg
Jul 20, 2010·Immunological Reviews·Loise M FranciscoArlene H Sharpe
Jan 22, 2011·Blood·Stephen Mackinnon, Ronjon Chakraverty
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
May 26, 2012·Nature Reviews. Immunology·Hao Wei Li, Megan Sykes
Jul 10, 2012·Haematologica·Betul Oran, Daniel J Weisdorf
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mei GuoHui-Sheng Ai
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas R Spitzer
Mar 8, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ulas D BayraktarEsperanza B Papadopoulos
Oct 22, 2013·International Journal of Hematology·Wenjuan Yang, Yunxiao Xu
Sep 15, 2014·Leukemia Research·Xuedong SunHuisheng Ai
Jan 21, 2015·Current Opinion in Hematology·Valeria Santini
Feb 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yu ZhuSixuan Qian
Feb 24, 2017·Current Hematologic Malignancy Reports·Kevin A DavidRoger Strair
Jan 7, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·David KlimanEmily Blyth

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mei GuoHui-Sheng Ai
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C D Bloomfield
Current Opinion in Hematology
Betul Oran, Daniel J Weisdorf
© 2022 Meta ULC. All rights reserved